产品描述
ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.

体外活性

ML228 represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications[1][2].

体内活性
ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduces SCI secondary injury and promotes the recovery of neurological function[3].

Cas No.
1357171-62-0

分子式
C27H21N5

分子量
415.49

参考文献
[1]Chen H, et al. Effect of hypoxia-inducible factor-1/vascular endothelial growth factor signaling pathway on spinal cord injury in rats.Exp Ther Med. 2017 Mar;13(3):861-866.
[2]Theriault JR, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012 Jan 1;22(1):76-81.
[3]Theriault JR, et al. Discovery of a Small Molecule Activator of the Hypoxia Inducible Factor Pathway. Probe Reports from the NIH Molecular Libraries Program.

储存和溶解度
DMSO:30 mg/mL (72.2 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years

Note
For research use only .